Matthew O'Hayer, founder and 10% shareholder of Vital Farms, Inc., filed a Form 144 notice on November 6, 2026, disclosing a proposed sale of 372,000 shares of common stock under a Rule 10b5-1 plan adopted July 17, 2026.
The Eric Lawrence & Leslie Ludwig Rev Trust, affiliated with an Eagle Bancorp, Inc. director, filed a Form 144 notice on November 6, 2026, disclosing a proposed sale of 2,000 shares of Eagle Bancorp common stock on NASDAQ.
Titus Benjamin Ball, an officer of BeOne Medicines Ltd., filed a Form 144 notice of proposed sale of 1,559 American Depositary Shares on November 6, 2026, with the securities to be sold on NASDAQ through Morgan Stanley Smith Barney LLC Executive Financial Services.
Brian Poff, an officer of Addus HomeCare Corporation, filed a Form 144 notice on November 6, 2026, proposing the sale of 6,644 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services.
Michael D. Wattenbarger, an officer of Addus HomeCare Corporation, filed a Form 144 notice on November 6, 2026, disclosing a proposed sale of 7,141 shares of common stock with an aggregate market value of $890,254.94.
Forrester Research, Inc. filed a registration statement on November 6, 2026, to register an additional 450,000 shares of common stock for issuance under its Amended and Restated Employee Stock Purchase Plan, which was approved by stockholders at the company's 2026 Annual Meeting.
Addus HomeCare Corporation officer Monica Raines filed a Form 144 notice on November 6, 2026, disclosing a proposed sale of 2,062 shares of common stock acquired through a stock option exercise on the same date.
Jane Street Group, LLC and affiliated entities filed Amendment No. 3 to Schedule 13G with the SEC on November 6, 2026, disclosing their beneficial ownership positions in Super Micro Computer, Inc. as of September 30, 2026.
Director Joseph E. Gilliam filed an initial statement of beneficial ownership with the SEC on November 6, 2026, disclosing his securities holdings in 10x Genomics, Inc. as of the event date of October 28, 2026.
Ansuman Satpathy, a newly appointed director of 10x Genomics, Inc., filed a Form 3 Initial Statement of Beneficial Ownership with the SEC on November 6, 2026, disclosing no securities beneficially owned as of the event date of October 28, 2026.